FDA Grants Fast Track Designation to Suplexa for MSI-H Colorectal Cancer

Targeted Oncology has reported on the FDA’s decision to grant Fast Track designation to suplexa, our non-engineered autologous cellular immunotherapy, for the treatment of patients with MSI-H colorectal cancer. The article highlights the data from our completed phase 1 SUPLEXA-101 trial that supported the designation, including two responses in patients with MSI-H colorectal cancer treated… Read more »